ORIC PHARMACEUTICALS INC's ticker is ORIC and the CUSIP is 68622P109. A total of 81 filers reported holding ORIC PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $21,049,699 | -9.0% | 3,479,289 | +16.8% | 0.04% | -5.0% |
Q2 2023 | $23,119,283 | +69.1% | 2,979,289 | +24.2% | 0.04% | +33.3% |
Q1 2023 | $13,675,737 | -3.2% | 2,399,252 | 0.0% | 0.03% | -45.5% |
Q4 2022 | $14,131,594 | +109.6% | 2,399,252 | +13.9% | 0.06% | +150.0% |
Q3 2022 | $6,742,000 | -28.6% | 2,106,968 | 0.0% | 0.02% | -12.0% |
Q2 2022 | $9,439,000 | -7.3% | 2,106,968 | +10.5% | 0.02% | +25.0% |
Q1 2022 | $10,183,000 | -51.5% | 1,906,968 | +33.6% | 0.02% | -48.7% |
Q4 2021 | $20,977,000 | +0.6% | 1,426,968 | +43.1% | 0.04% | +11.4% |
Q3 2021 | $20,847,000 | +18.2% | 996,989 | 0.0% | 0.04% | +34.6% |
Q2 2021 | $17,637,000 | -27.9% | 996,989 | -0.1% | 0.03% | -27.8% |
Q1 2021 | $24,452,000 | -19.6% | 998,061 | +11.1% | 0.04% | -26.5% |
Q4 2020 | $30,399,000 | +301.1% | 898,061 | +196.3% | 0.05% | +250.0% |
Q3 2020 | $7,579,000 | – | 303,061 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Memorial Sloan Kettering Cancer Center | 602,272 | $3,643,746 | 14.84% |
Column Group LLC | 3,568,181 | $21,587,495 | 14.33% |
Nextech Invest Ltd. | 4,285,714 | $25,928,570 | 7.86% |
Prosight Management, LP | 2,579,802 | $15,607,802 | 4.95% |
Invus Financial Advisors, LLC | 1,007,575 | $6,095,829 | 3.82% |
SILVERARC CAPITAL MANAGEMENT, LLC | 1,123,345 | $6,796,237 | 2.06% |
VR Adviser, LLC | 2,142,856 | $12,964,279 | 1.36% |
Altium Capital Management LP | 418,706 | $2,533,171 | 1.32% |
Euclidean Capital LLC | 1,978,820 | $11,971,862 | 1.31% |
Frazier Life Sciences Management, L.P. | 2,142,855 | $12,964,273 | 0.86% |